A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

NCT05828875 | Unknown

• 1 other identifier: bc2022181
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various medical centers, and who survived without disease progression at the time of the survey. The purpose of this study is to evaluate the current quality of life, as well as the incidence of long-term toxic side effects, nutritional status, and psychological status of esophageal cancer patients cured by radiotherapy.

Conditions

Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival

Outcome Measures

Primary Outcomes (1)

• Quality of Life Assessment survey

  Two years after the end of radiotherapy

Interventions

questionnaire investigation OTHER

Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old; * Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection; * Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression; * Radiotherapy dose ≥ 45Gy.

You may qualify if:

• Voluntarily accept this survey and research;
• The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old;
• Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection;
• Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression;
• Radiotherapy dose ≥ 45Gy.

You may not qualify if:

• Patients who do not cooperate with this survey;
• Patients who have died at the time of investigation;
• Patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey;
• Patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey;
• Patients with incorrect contact information and missing visits

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300000, China

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2023
• First Posted: April 25, 2023
• Study Start: August 1, 2023
• Primary Completion: May 1, 2024
• Study Completion: July 1, 2024
• Last Updated: July 7, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)